Ruxience 500 MG/50 ML vial 50ML
Ended Awarded Last action
- Contract number
- SPE2DR26F20UV
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,578
Award facts
- Contract value 100% obligated
- $11,578.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,578.20 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials on January 15, 2026, with an ultimate completion date of January 16, 2026. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems.
This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for the military healthcare supply chain. The IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies—including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains—to support Defense Health Agency operations, U.S. Coast Guard, and other government healthcare systems worldwide. Ruxience, a biosimilar to rituximab, supports oncology and immunology treatment protocols within the federal medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F20UV?
SPE2DR26F20UV was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26F20UV worth?
The government has obligated $11,578 on SPE2DR26F20UV.
Is contract SPE2DR26F20UV an order under another contract?
Yes. SPE2DR26F20UV is a delivery order under SPE2DR25D3301, an indefinite delivery contract.
Was contract SPE2DR26F20UV competed?
The extent of competition for SPE2DR26F20UV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award